Evaluation of reimbursement policy about anti-tnf agents in Turkey

Basit Öğe Kaydı
dc.contributor.authorBilginer, Emrah
dc.date.accessioned2019-08-01T12:32:54Z
dc.date.available2019-08-01T12:32:54Z
dc.date.issued2019en_US
dc.departmentHitit Üniversitesi, Sağlık Bilimleri Fakültesi, Hemşirelik Bölümü
dc.description.abstractAnti-TNF (anti-tumour necrosis factor) agents are currently used in many rheumatic diseases. This research aims mainly to evaluate the reimbursement policy about anti-TNF drugs in Turkey. The analysis has been carried out according to the antiTNF reimbursement rules with the consumption data for the years 2012 - 2017. The cost tables have been prepared with the reimbursement prices and the medication prospectus doses approved by Turkish Ministry of Health. The results of the research indicate that anti-TNF agents have different treatment costs and adalimumab offers the lowest 12-month treatment costs for the diseases mentioned in the study. For a fair, obtainable and sustainable medication policy, Social Security Administration (SSA) has to reimburse the other molecules from the 12-month treatment cost of adalimumab. The current policies are far from being pharmacoeconomic and if this continues the resources will not be used in an efficient way for public health in Turkey.
dc.description.provenanceSubmitted by Zeynep Umut Arslan (umutarslan@hitit.edu.tr) on 2019-08-01T12:24:18Z No. of bitstreams: 1 emrah-bilginer2019.pdf: 222316 bytes, checksum: 513a2b10f98ed4a0738a0fa409a7b771 (MD5)en
dc.description.provenanceApproved for entry into archive by Zeynep Umut Arslan (umutarslan@hitit.edu.tr) on 2019-08-01T12:32:54Z (GMT) No. of bitstreams: 1 emrah-bilginer2019.pdf: 222316 bytes, checksum: 513a2b10f98ed4a0738a0fa409a7b771 (MD5)en
dc.description.provenanceMade available in DSpace on 2019-08-01T12:32:54Z (GMT). No. of bitstreams: 1 emrah-bilginer2019.pdf: 222316 bytes, checksum: 513a2b10f98ed4a0738a0fa409a7b771 (MD5) Previous issue date: 2019en
dc.identifier.citationBilginer, E. (2019). Evaluation of reimbursement policy about anti-tnf agents in Turkey. Farmacia, 67(4), 743-748.
dc.identifier.doi10.31925/farmacia.2019.4.25
dc.identifier.endpage748en_US
dc.identifier.issn0014-8237
dc.identifier.issn2065-0019
dc.identifier.issue4en_US
dc.identifier.startpage743en_US
dc.identifier.urihttps://doi.org/10.31925/farmacia.2019.4.25
dc.identifier.urihttps://hdl.handle.net/11491/3688
dc.identifier.volume67en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherSoc Stiinte Farmaceutice Romania
dc.relation.ispartofFarmacia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnti-TNF Agentsen_US
dc.subjectCost Analysisen_US
dc.subjectTurkish Health Systemen_US
dc.subjectPharmacoeconomicsen_US
dc.titleEvaluation of reimbursement policy about anti-tnf agents in Turkey
dc.typeArticle

Dosyalar

Koleksiyon

Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu